NeuroOne Medical Technologies (NMTC) - רווח נקי למניה (EPS TTM)

Rising sales of Evo electrodes and the launch of OneCore systems are driving the growth of NeuroOne Medical Technologies (NMTC), as illustrated by the rolling annual earnings per share. Meanwhile, -0.92 represents the current value of this metric. Operations within the US legal framework, shielded from the impact of trade wars, ensure stability. The defensive nature of neurosurgery renders demand crisis-proof, guaranteeing revenue predictability.

This indicator reflects the portion of net income attributable to a single common share over a rolling year. For NeuroOne Medical Technologies (NMTC), this calculation verifies the monetization efficiency of its diversified neurotechnology platforms. By analyzing the per-share profit trend over the last 12 months, an investor assesses the real balance of supply and demand. Product diversification within neurology minimizes the risk of overpaying for the asset. Positive momentum confirms the fundamental stability of the business.